Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Avita Medical, Inc.

NASDAQ: RCEL · Industrial Applications and Services · 4 alerts · CIK 1762303

Share price
$15.22Close, Nov 16
Market cap
$478M
Shares outstanding
31.42MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Avita Medical, Inc. filings on SEC EDGAR ↗

4:19 PM ET 10-Q
Financial Results

Avita Medical Q3 2026 Results: Net Loss of $6.22M, Loss Narrows

AVITA Medical reported total revenues of $67.1 million for the nine months ended September 30, 2026, a 24% increase compared to the prior year. Despite the revenue growth, the company recorded a net loss of $24.5 million for the period, though this was an improvement from the $37.0 million net loss in the same period of 2025.

Key figure
Net loss $6.22M
4:14 PM ET 8-K
Financial Results

Avita Medical Financial Results

AVITA Medical reported third quarter 2026 revenue of $26.1 million, a 53% increase year-over-year, driven by growth in its RECELL and Cohealyx products. The company raised its full-year 2026 revenue guidance to $92-$94 million and announced that improved liquidity has alleviated previous 'going concern' doubts. Additionally, the company met revenue milestones to access a final $10 million tranche of its credit facility with Perceptive Advisors.

Term
Q3 2026

“AVITA delivered another strong quarter, with revenue increasing 53% year over year and gross margin reaching 84%. RECELL continued to drive our growth, supported by increasing adoption of Cohealyx, while disciplined expense management contributed to a substantial improvement in cash use. Based on our year-to-date performance and continued commercial momentum, we are raising our full-year revenue guidance and remain on track to achieve cash flow breakeven in the fourth quarter.”

Cary Vance, President and Chief Executive Officer of AVITA Medical

“Reaching $85 million in trailing twelve-month revenue reflects the continued execution of our commercial strategy and satisfied the revenue condition required to draw down the remaining $10 million under our credit facility with Perceptive Advisors LLC. This additional, minimally dilutive capital strengthens our liquidity as we advance toward cash flow breakeven and cash generation in the fourth quarter.”

David O'Toole, Chief Financial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.